Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro

Journal of Neuroscience Research

Volumn 88, Issue 11, 2010, Pages 2316-2324

  Popescu, Andreea C ^a,b   Sidorova, Elena ^a,b   Zhang, Guangming ^a   Eubanks, James H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aminoglycoside; Methyl dna binding factor; Nonsense mutation read through; Rett syndrome

Indexed keywords

AMINOGLYCOSIDE; METHYL CPG BINDING PROTEIN 2; AMIKACIN; GENTAMICIN; MECP2 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN SYNTHESIS INHIBITOR; STOP CODON;

ARTICLE; CELL STRAIN HEK293; DOSE RESPONSE; DRUG EFFICACY; EMBRYO; FEMALE; GENE REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOID CELL LINE; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETT SYNDROME; BIOSYNTHESIS; CELL LINE; CELL NUCLEUS; CHEMISTRY; CHILD; DRUG EFFECTS; GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; WESTERN BLOTTING;

AMIKACIN; AMINOGLYCOSIDES; BLOTTING, WESTERN; CELL LINE; CELL NUCLEUS; CHILD; CODON, NONSENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENTAMICINS; HUMANS; METHYL-CPG-BINDING PROTEIN 2; PROTEIN SYNTHESIS INHIBITORS; RETT SYNDROME; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 77955392133     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22409     Document Type: Article

References (26)

1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. 1999. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nature 23:185-188.
2. Barton-Davis ER, Cordiner L, Shoturma DI, Leland ST, Sweeney HL. 1999. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375-381.
3. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. 1997. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3:1280-1284.
4. Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, Rousset JP. 2004. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 11:619-627.
5. Brendel C, Klahold E, Gartner J, Huppke P. 2009. Suppression of nonsense mutations in Rett syndrome by aminoglycoside antibiotics. Pediatr Res 65:520-533.
6. Bustin SA, Nolan T. 2004. Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Technol 15:155-166.
7. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY. 2004. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet 13:2679-2689.
8. Du M, Keeling KM, Fan L, Liu X, Kovacs T, Sorscher E, Bedwell DM. 2006. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 84:573-582.
9. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. 2007. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci U S A 104:1931-1936.
10. Guy J, Gan J, Selfridge J, Cobb S, Bird A. 2007. Reversal of neurological defects in a mouse model of Rett syndrome. Science 23:1143-1147.
11. Hainrichson M, Nudelman I, Baasov T. 2008. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem 6:227-239.
12. Heier CR, DiDonato CJ. 2009. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet 18:1310-1322.
13. Howard M, Frizzell AR, Bedwell DM. 1996. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2:467-469. (Pubitemid 26191920)
14. Howard MT, Shrits BH, Petros LM, Flanigan KM, Gesteland FR, Atkins JF. 2000. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48:164-169.
15. Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. 2008. Targeted delivery of a Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet 17:1386-1396. (Pubitemid 351627335)
16. Keeling KM, Bedwell DM. 2002. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med 80:367-376.
17. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. 2008. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372:719-727.
18. Lai CH, Chun HH, Nahas AS, Mitui M, Gamo DM, Du L, Gatti AR. 2004. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A 101:15676-15681.
19. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. 2004. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl Acad Sci U S A 101:6033-6038.
20. Manuvakhova M, Keeling K, Bedwell DM. 2000. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-1055.
21. Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM. 2006. Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation. Epigenetics 1:1-11.
22. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, Schacht J, Pilch DS, Ben-Yosef T, Baasov T. 2009. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52:2836-2845.
23. Percy AK, Lane JB, Childers J, Skinner S, Annese F, Barrish J, Caeg E, Glaze DG, MacLeod P. 2007. Rett syndrome: North American database. J Child Neurol 22:1338-1341.
24. Pinotti M, Rizzotto L, Pinton P, Ferraresi P, Chuansumrit A, Charoenkwan P, Marchetti G, Rizzuto R, Mariani G, Bernardi F, International Factor VII Deficiency Study Group. 2006. Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. J Thromb Haemost 4:1308-1314.
25. Rebibo-Sabbah A, Nudelman I, Ahmed MZ, Baasov T, Ben-Yosef T. 2007. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet 122:373-381.
26. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. 2007. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-93.